Oct 2026
Personalized neoantigen-targeting cancer vaccines in ovarian cancer: a phase 1 trial.
Maclean C. Sellars, Jessica A. Frank, Bohoon Shim et al.
· Nature Medicine · 0 citations
4 papers indexed here
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Open access
Sep 2026
72 Time-of-day of Immune Checkpoint Inhibitor Infusion and Overall Survival in Renal Cell Carcinoma: A Real-World Cohort Analysis
Abstract Background Previous retrospective work found an association between earlier immune-checkpoint inhibitors (ICI) infusion times and survival outcomes in renal cell carcinoma (RCC). A recent randomized trial in non-small cell lung cancer (NSCLC) also reported benefit, however, a recent analysis of several randomi...
P. Barrios, Mustafa Saleh, Liliana Ascione et al.
· The Oncologist · 0 citations
Open access
Oct 2026
Programmable antigen-presenting scaffolds expand rare tumor-antigen-specific T cells from peripheral blood
Jessica DeVilla, Y. Binenbaum, N. Cieri et al.
· bioRxiv · 0 citations
Jul 2026
Tertiary lymphoid structures harbour stem-like tumour-specific T cells
Tertiary lymphoid structures are reservoirs of tumour-specific T cells with stem-like progenitor features that could be leveraged by T cell immunotherapies, and are found to be reservoirs of tumour-specific T cells with stem-like progenitor features that could be leveraged by T cell immune pressure.
Alexander B. Afeyan, Adi Nagler, Chloe R. Tu et al.
· Nature · 2 citations